Dr. Reddy's Laboratories secured European Commission approval for AVT03, a biosimilar to Prolia and Xgeva, for osteoporosis and bone compli...

Dr. Reddy's Laboratories has secured European Commission marketing approval for AVT03, a biosimilar to Prolia and Xgeva, used for bone-rela...

Prolia is a prescription medicine used to treat osteoporosis in women who have been through menopause and in men who are at increased risk ...

Biocon is entering a transformative phase, leveraging regulatory shifts in the US and a strong insulin and GLP-1 portfolio to accelerate gr...

Biocon Group reported a strong Q2 FY26 with a 20% year-on-year increase in operating revenue to Rs 4,296 crore, driven by biosimilars and g...

Shares of Biocon Ltd rose 2% to Rs 361.25 on the BSE after its subsidiary, Biocon Biologics, received U.S. FDA approval for two denosumab b...

Biocon Biologics Ltd has achieved a significant milestone. It has secured marketing authorizations in the UK for Vevzuo and Evfraxy. These ...

Biocon Ltd's arm, Biocon Biologics Ltd, has received European Commission authorisation for its Vevzuo and Evfraxy biosimilars, used to trea...

Dr Reddy’s stock rose 5.5% in six sessions post-Q4 results, outperforming the BSE Healthcare index. Strong revenue growth, biosimilar launc...

Biocon is planning a ₹4,500 crore fundraise to increase promoter stake in Biocon Biologics and convert structured venture debt into equity,...

Axis Securities and JM Financial both maintain 'Buy' ratings on Biocon, with target prices of Rs 370 and Rs 380, respectively. Biocon has a...

Alvotech and Dr. Reddy's partner for AVT03, a biosimilar to Prolia and Xgeva, treating osteoporosis and skeletal-related events. The agreem...

Biocon Biologics plans to raise a further $300m by the end of FY24 in order to reduce its net debt, which peaked at $1.9bn in December 2022...

Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- develo...

The biosimilars planned under this agreement include biosimilar Prolia (denosumab 60mg/ml) and Xgeva (denosumab 70 mg/ml) for treating oste...

Denosumab is indicated for the treatment of postmenopausal women with osteoporosis at high risk of fracture and prevention of skeletal-rela...

Cipla Gulf FZ LCC is expanding its partnership with Alvotech for the marketing and distribution of four biosimilar medicines in Australia a...